Aging immune systems under the microscope: new study tracks COVID antibodies in nursing homes

NCT ID NCT04563650

Ongoing Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 98 elderly residents in French nursing homes to see how long their COVID-19 antibodies last. Researchers will also measure immune markers linked to aging to understand why some older people have weaker immune responses. The goal is to learn how to better protect this vulnerable group through vaccination and care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help tailor COVID-19 vaccination strategies for older adults and improve protection in nursing homes.
What could go wrong: This is an observational study, not a treatment trial. It only measures antibodies and immune markers, so it won't directly change care. Results may not apply to all elderly populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 HIV Seropositivity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19 GERIATRIC MEDICINE IMMUNOSENESCENCE SEROCONVERSION

Contacts and locations

Locations

CHU Amiens

Amiens, 80480, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.